- CytoSorbents ( NASDAQ: CTSO ) notifies that the U.S. Army Medical Research Acquisition Activity has awarded the company a three-year Phase III contract valued at $4,292,641 to enable freeze-dried universal plasma using its HemoDefend-BGA technology.
- Without the need for blood typing, widespread availability of universal plasma could help save lives via faster emergency treatment in both civilian and military settings.
- The outcome of this award is expected to be the large-scale manufacturing of the active polymer for subsequent integration of the device into the plasma freeze-drying process.
For further details see:
CytoSorbents secures $4.3M contract by U.S. Department of Defense